JW Asset Management’s Impax Laboratories, Inc. IPXL Stock Holding History

JW Asset Management’s Portfolio IPXL Stock Details IPXL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q2	–	Sell	-30,000	Closed	-$380K	–	46
2017 Q1	$380K	Buy	+30,000	New	+$362K	0.08%	35
2016 Q2	–	Sell	-53,373	Closed	-$1.71M	–	47
2016 Q1	$1.71M	Hold	53,373	–	–	1.12%	20
2015 Q4	$2.28M	Sell	53,373 -10,000	-16%	-$399K	0.85%	22
2015 Q3	$2.23M	Buy	63,373 +5,550	+10%	+$250K	0.81%	23
2015 Q2	$2.65M	Buy	57,823 +31,580	+120%	+$1.5M	0.81%	22
2015 Q1	$1.23M	Buy	26,243 +209	+0.8%	+$8.32K	0.53%	29
2014 Q4	$825K	Buy	+26,034	New	+$762K	0.62%	30

Other funds holding IPXL

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Maverick Capital Dallas, Texas $8.67B AUM 48.76% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

FCM

Frontier Capital Management Boston, Massachusetts $9.73B AUM 55.65% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

JW Asset Management's IPXL Position: Q2 2017 in Review

JW Asset Management sold out of Impax Laboratories, Inc. (IPXL) in Q2 2017, closing a stake of 30,000 shares — an estimated $380K sold.

JW Asset Management first reported a position in IPXL in Q4 2014 and held it in 7 quarters. The position peaked at $2.65M in Q2 2015. 172 funds tracked by Wall St. Rank hold IPXL as of Q2 2017.

JW Asset Management reported no remaining Impax Laboratories, Inc. position as of Q2 2017 after selling out during the quarter.
JW Asset Management sold 30,000 Impax Laboratories, Inc. shares in Q2 2017, an estimated $380K.
JW Asset Management first reported a position in Impax Laboratories, Inc. in Q4 2014 and held it in 7 quarters.
JW Asset Management's Impax Laboratories, Inc. position peaked at $2.65M in Q2 2015.
172 funds tracked by Wall St. Rank held Impax Laboratories, Inc. as of Q2 2017.

Based on JW Asset Management's 13F filing for Q2 2017, filed 4 Aug 2017.